Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin
Abstract
Current strategies and guidelines for the treatment of community-acquired pneumonia are directed toward making care cost effective, by treating patients on an outpatient basis whenever possible. The use of the new fluoroquinolones could help to achieve these goals. These agents are highly bioavailable and can facilitate the oral treatment of certain patients who otherwise might be admitted to the hospital, as outpatients. The good absorption and bioavailability of these agents can allow moderately ill patients to rapidly achieve effective serum levels of the drug after oral administration and can also facilitate early discontinuation of intravenous therapy and early discharge for responding inpatients. For inpatients or outpatients with clinical risk factors for acquiring drug-resistant pneumococci, quinolones represent a reliable monotherapy option and an effective alternative to a beta-lactam/macrolide combination. Although the in vitro differences among the various quinolones remain of unclear clinical relevance, preliminary data suggest that agents with enhanced in vitro activity against pneumococci, such as moxifloxacin, may have greater clinical efficacy and may lead to more-rapid resolution of fever and, potentially, less selection of future pneumococcal resistance to quinolones than that associated with agents with less intrinsic activity.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.